Citigroup
CDAK

Citigroup’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Citigroup’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-449
Closed -$179 – 6011
2022
Q4 		$179 Buy
449
+22
+5% +$14 ﹤0.01% 5607
2022
Q3 		$0 Sell
427
-716
-63% -$1.5K ﹤0.01% 6553
2022
Q2 		$3K Sell
1,143
-27
-2% -$95 ﹤0.01% 5833
2022
Q1 		$7K Sell
1,170
-3,596
-75% -$22.6K ﹤0.01% 5721
2021
Q4 		$53K Buy
4,766
+2,951
+163% +$40.9K ﹤0.01% 5040
2021
Q3 		$30K Buy
1,815
+1,068
+143% +$19.1K ﹤0.01% 5040
2021
Q2 		$14K Buy
747
+300
+67% +$5.76K ﹤0.01% 5521
2021
Q1 		$7K Sell
447
-577
-56% -$12.5K ﹤0.01% 5829
2020
Q4 		$33K Buy
+1,024
New +$13.5K ﹤0.01% 6338

Other funds holding CDAK

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's CDAK Position: Q1 2023 in Review

Citigroup sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 449 shares — an estimated $179 sold.

Citigroup first reported a position in CDAK in Q4 2020 and held it in 9 quarters. The position peaked at $53K in Q4 2021. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

  • Citigroup reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 449 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $179.
  • Citigroup first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • Citigroup's Codiak BioSciences, Inc. Common Stock position peaked at $53K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.